Table 2 BCAC SNPs associated with breast cancer risk overall or by clinical and pathological characteristics

CASP8 D302H

CG v. GG: OR 0.89, 95% CI 0.85-0.94

CC v. GT: OR 0.74, 95% CI 0.62-0.87

Cox et al., Nat Genet 2007

FGFR2, rs2981582

TNRC9, rs3803662

MAP3K1, rs889312

LSP, rs3817198

8q24, rs13281615

OR_hom 1.63, 95% CI 1.53-1.72, p=4.1 × 10^-76

OR_hom 1.39, 95% CI 1.25-1.45, p=1.4 × 10^-36

OR_hom 1.27, 95% CI 1.19-1.36, p=4.1 × 10^-20

OR_hom 1.17, 95% CI 1.08-1.25, p=4.1 × 10^-9

OR_hom 1.18, 95% CI 1.10-1.25, p=4.1 × 10^-12

Easton et al., Nat Genet 2007

FGFR2, 2981582

8q24, 13281615

TNRC9, rs3803662

ER positive:p=10^-13

PGR positive: p=10^-5

low grade: p=10^-8

metastases: p=0.013

ER positive: p=0.001

PGR positive: p=0.011

low grade: p=10^-4

ER negative: OR 1.14, 95% CI 1.09-1.21

Garcia-Closas et al., PLoS Genet 2008

AKAP9 M463I

TT v. GG:

OR 1.17, 95% CI 1.08-1.27, p=0.0003

familial cases: OR 1.27, 95% CI 1.12-1.45, p=0.0003

TT v. GT:

OR 1.10, 95% CI 1.04-1.17, p=0.001

familial cases: OR 1.16, 95% CI 1.06-1.27, p=0.001

Frank et al., JNCI 2008

3p24, rs4973768

17q23, rs6504950

OR_per-allele 1.11, 95% CI 1.08-1.13, p=4.1 × 10^-23

OR_per-allele 0.95, 95% CI 0.92-0.97, p=1.4 × 10^-8

Ahmed et al., Nat Genet 2009

2q35, rs13387042

OR _per-allele 1.12, 95% CI 1.09 -1.15; p_trend 1.0 × 10^-19 (European Caucasian)

ER positive: OR 1.14, 95% CI 1.10-1.17; p=10^-15

ER negative: OR 1.10, 95% CI 1.04-1.15; p=0.0003

PGR positive: OR 1.15, 95% CI 1.11-1.19; p=5 × 10^-14

PGR negative: OR 1.10, 95% CI 1.06-1.15; p=0.00002

Milane et al., JNCI 2009